Search research articles
Contact Us
Filters
Showing results (571-580 of 745) with videos related to
Page
of 75
Sort By:
JAMA Oncology
|
July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
Igor Puzanov, Antoni Ribas, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
Omid Hamid, Igor Puzanov, Reinhard Dummer, et al.
Radiation Oncology (London, England)
|
June 4, 2020
Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score
Jana Schaule, Stephanie G C Kroeze, Oliver Blanck, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2019
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2024
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research
Teresa Amaral, Lena Nanz, Lina Maria Serna Higuita, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
The EMBO Journal
|
July 4, 2019
Proteomic identification of a marker signature for MAPKi resistance in melanoma
Verena Paulitschke, Ossia Eichhoff, Christopher Gerner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
Page
of 75
Search research articles
Search
Showing results (571-580 of 745) with videos related to
Sort By:
Page
of 75
JAMA Oncology
|
July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
Igor Puzanov, Antoni Ribas, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
Omid Hamid, Igor Puzanov, Reinhard Dummer, et al.
Radiation Oncology (London, England)
|
June 4, 2020
Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score
Jana Schaule, Stephanie G C Kroeze, Oliver Blanck, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2019
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2024
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research
Teresa Amaral, Lena Nanz, Lina Maria Serna Higuita, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
The EMBO Journal
|
July 4, 2019
Proteomic identification of a marker signature for MAPKi resistance in melanoma
Verena Paulitschke, Ossia Eichhoff, Christopher Gerner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
Page
of 75